foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

One Year on from IPO: Motif Bio’s Commercialisatio...

Graham Lumsden, CEO of Motif Bio, talks to Biotech and Money about the comm...

Read More

ISSUE 9, 2016 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

Growth through commercialised tech and acquisition...

Biotech and Money had the opportunity to speak to Neil Campbell of Helomics...

Read More

4 things I learned from Eddy Littler, CEO of Domai...

Biotech and Money recently had the opportunity to catch up with Eddy Little...

Read More

Life science IPOs: listing in UK or US

The decision to take a company public is never taken lightly. For life scie...

Read More

Turning the tide: attracting transatlantic biotech...

London Stock Exchange is a diversified international exchange Group that si...

Read More

The Californian biotech who brought a $100m IPO to...

Verseon was founded in 2002. Its proprietary drug discovery platform, devel...

Read More

View of an active private life science investor

In March, Jon Moulton increased his shareholding in Redx Pharma as the biot...

Read More

From developing highly differentiated ‘best-in-cl...

Redx is focused on the development of proprietary, small molecule therapeut...

Read More

Using conformational design to target a $9bn thera...

C4X Discovery, a Manchester-based, AIM-listed Company which uses an NMR-bas...

Read More

US Life Science Listings take to AIM

For those of you not well versed in Latin, ‘Omne Trium Perfectum’ refers to...

Read More

ISSUE 6, 2015 Drugs & Dealers Magazine Released

Biotech and Money are pleased to announce the release of the latest Drugs &...

Read More

Add Your Response